Facile processing for instant production of clinically-approvable nanoagents for combination cancer therapy (original) (raw)
Related papers
Prussian blue nanoparticles: Synthesis, surface modification, and application in cancer treatment
International Journal of Pharmaceutics, 2018
This review outlines recently developed Prussian blue nanoparticle (PB NPs)-based multimodal imaging-guided chemo-photothermal strategies for cancer diagnosis and treatment in order to provide insight into the future of the field. The primary limitation of existing therapeutics is the lack of selectivity in drug delivery: they target healthy and cancerous cells alike. In this paper, we provide a thorough review of diverse synthetic and surface engineering techniques for PB NP fabrication. We have elucidated the various targeting approaches employed to deliver the therapeutic and imaging ligands into the tumor area, and outlined methods for enhancement of the tumor ablative ability of the NPS, including several important combinatorial approaches. In addition, we have summarized different in vitro and in vivo effects of PB NP-based therapies used to overcome both systemic and tumor-associated local barriers. An important new approach-PB NP-based immune drug delivery, which is an exciting and promising strategy to overcome cancer resistance and tumor recurrence-has been discussed. Finally, we have discussed the current understanding of the toxicological effects of PB NPs and PB NP-based therapeutics. We conclude that PB NP-based multimodal imaging-guided chemo-photothermal therapy offers new treatment strategies to overcome current hurdles in cancer diagnosis and treatment.
Photochemistry and Photobiology, 2007
This article presents the development and characterization of nanoparticles loaded with methylene blue (MB), which are designed to be administered to tumor cells externally and deliver singlet oxygen ('0,) for photodynamic therapy (PDT), i.e. cell kill via oxidative stress to the membrane. We demonstrated the encapsulation of MB, a photosensitizer (PS), in three types of sub-200 nm nanoparticles, composed of polyacrylamide, sol-gel silica and organically modified silicate (ORMOSIL), respectively. Induced by light irradiation, the entrapped MB generated lo2, and the produced lo2 was measured quantitatively with anthracene-9,lO-dipropionic acid, disodium salt, to compare the effects of different matrices on '0, delivery. Among these three different kinds of nanoparticles, the polyacrylamide nanoparticles showed the most efficient delivery of lo2, but its loading of MB was low. In contrast, the sol-gel nanoparticles had the best MB loading but the least efficient lo2 delivery. In addition to investigating the matrix effects, a preliminary in vitro PDT study using the MBloaded polyacrylamide nanoparticles was conducted on rat C6 glioma tumor cells with positive photodynamic results. The encapsulation of MB in nanoparticles should diminish the interaction of this PS with the biological milieu, thus facilitating its systemic administration. Furthermore, the concept of the drug-delivering nanoparticles has been extended to a new type of dynamic nanoplatform (DNP) that only delivers lo2. This DNP could also be used as a targeted multifunctional platform for combined diagnostics and therapy of cancer.
Nanomaterials
Prussian blue nanoparticles (PBNPs) are effective photothermal therapy (PTT) agents: they absorb near-infrared radiation and reemit it as heat via phonon-phonon relaxations that, in the presence of tumors, can induce thermal and immunogenic cell death. However, in the context of central nervous system (CNS) tumors, the off-target effects of PTT have the potential to result in injury to healthy CNS tissue. Motivated by this need for targeted PTT agents for CNS tumors, we present a PBNP formulation that targets fibroblast growth factor-inducible 14 (Fn14)-expressing glioblastoma cell lines. We conjugated an antibody targeting Fn14, a receptor abundantly expressed on many glioblastomas but near absent on healthy CNS tissue, to PBNPs (aFn14-PBNPs). We measured the attachment efficiency of aFn14 onto PBNPs, the size and stability of aFn14-PBNPs, and the ability of aFn14-PBNPs to induce thermal and immunogenic cell death and target and treat glioblastoma tumor cells in vitro. aFn14 remain...
New nanoporous iron oxide nanoparticles with superparamagnetic behavior were successfully synthesized from Prussian blue (PB) nanocubes throughathermalcon-version methoda nd applied to the intracellular drug-delivery systems (DDS) of bladder cancer cells (i.e.,T 24) with controlled release and magnetic guiding properties. The results of the MTT assay and confocal laser scanning mi-croscopy indicate that the synthesized iron oxide nanopar-ticles were successfully uptaken by T24 cellswith excellent biocompatibility.A na nticancer drug, that is, cisplatin, was used as am odel drug, and itsl oading/release behavior was investigated. The intracellular drug delivery efficiency was greatly enhanced for the cisplatin-loaded, PB-derived, magnetic-guided drug-delivery system compared with the non-drug case. The synthesized nanomaterials show great potential as drug vehicles with high biocompatibility,c on-trolled release, and magnetic targeting features for future intracellular DDS. In recent years, cancerh as become one of the most serious diseases causing ah igh rate of casualties. Chemotherapy,r adi-otherapy and surgical resection are three common therapies to treat cancer, chemotherapy being the one inflincting the least pain to the patients. However,t he multidrug resistance (MDR) of cancer cells is responsible for 90 %o fc hemothera-peutic failures upon treatment. [1] Generally,M DR originates from the overexpression of ATP-bindingc assette transporter proteins effluxing the anticancer drugs from the cytoplasm of cancer cellstor educe the accumulation of drugs. [2] Fortunately, an appropriate drug delivery system (DDS) can change the release behavior of chemotherapeutic agents, thus improving effectively the anticancer activity and overcoming the prevalent
Fluorescent, Prussian Blue-Based Biocompatible Nanoparticle System for Multimodal Imaging Contrast
Nanomaterials
(1) Background. The main goal of this work was to develop a fluorescent dye-labelling technique for our previously described nanosized platform, citrate-coated Prussian blue (PB) nanoparticles (PBNPs). In addition, characteristics and stability of the PB nanoparticles labelled with fluorescent dyes were determined. (2) Methods. We adsorbed the fluorescent dyes Eosin Y and Rhodamine B and methylene blue (MB) to PB-nanoparticle systems. The physicochemical properties of these fluorescent dye-labeled PBNPs (iron(II);iron(III);octadecacyanide) were determined using atomic force microscopy, dynamic light scattering, zeta potential measurements, scanning-and transmission electron microscopy, X-ray diffraction, and Fourier-transformation infrared spectroscopy. A methylene-blue (MB) labelled, polyethylene-glycol stabilized PBNP platform was selected for further assessment of in vivo distribution and fluorescent imaging after intravenous administration in mice. (3) Results. The MB-labelled particles emitted a strong fluorescent signal at 662 nm. We found that the fluorescent light emission and steric stabilization made this PBNP-MB particle platform applicable for in vivo optical imaging. (4) Conclusion. We successfully produced a fluorescent and stable, Prussian blue-based nanosystem. The particles can be used as a platform for imaging contrast enhancement. In vivo stability and biodistribution studies revealed new aspects of the use of PBNPs.